Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

Dr. Turgeon is an esteemed Clinical Professor at University of Michigan Health and clinical translational researcher with specific research interest in colon cancer and chemoprevention Mainz Biomed’s Medical Advisory Board to bring together a highly distinguished group of multi-disciplinary experts from across gastroenterology, clinical research and diagnostics to support its forthcoming U.S. pivotal trial for […]

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites  BERKELEY, Calif. and MAINZ, Germany and NEW YORK, August 16, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics […]

Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development

Dr. Frank Krieg-Schneider to lead development across Mainz Biomed’s portfolio of advanced cancer detection products including its flagship product ColoAlert and future diagnostic tests BERKELEY, US – MAINZ, Germany – AUGUST 3, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, […]

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

Renowned Experts to Support ColoAlert’s U.S. Pivotal Clinical Trial and Development of Additional Cancer Diagnostics Dr. Wang is the GI (Gastrointestinal) Division Chief at Columbia University Vagelos College of Physicians and Surgeons and serves as Co-leader of the Tumor Biology and Microenvironment Program of the Herbert Irving Comprehensive Cancer Center BERKELEY, US – MAINZ, Germany […]

Mainz Biomed Provides Corporate Update for First Half of 2022

Company to Host Webcast on July 12 at 4.00pm ET BERKELEY, US – MAINZ, Germany – JULY 5, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to host a webcast on July 12, 2022 at 4:00pm ET to […]

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

Multi-center clinical trial impacting ColoAlert’s profile for FDA submission On track to report results by early 2023 BERKELEY, Calif. and MAINZ, Germany, June 28, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has enrolled the first patient […]

Mainz Biomed Announces Annual General Meeting

BERKELEY, US – MAINZ, Germany – May 23, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces that its annual general meeting (the “AGM”) will be held at the offices of CMS Netherlands, Atrium, Parnassusweg 737, 1077 DG Amsterdam, the […]

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE)

Dante Labs is a Global Leader in Genomics and Precision Medicine Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer BERKELEY, Calif. and MAINZ, Germany and New York, MAY 19, 2022 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the early […]